Navigation Links
Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
Date:7/22/2013

SAN DIEGO, July 22, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor™. Imprimis has engaged Agility Clinical, Inc., a Carlsbad, CA-based consulting and contract research organization (CRO), to conduct the study at 20 - 30 US sites. The IRB-approved Phase III trial is a randomized, multicenter, double-blind, parallel-group study to assess the efficacy and safety of Impracor (ketoprofen 10% cream) compared with placebo in the treatment of acute pain (flare) associated with osteoarthritis (OA) of the knee.

As previously announced, Imprimis designed the Phase III study with the assistance of key opinion leaders, and also relied upon feedback from the U.S. Food and Drug Administration (FDA) following a Type C meeting between Imprimis and FDA officials in April 2013.

"This is an important and critical step forward for Imprimis as we prepare to start enrollment of our Phase III clinical trial in the third quarter of this year," said Imprimis CEO Mark L. Baum. "The IRB approval of this protocol in many ways represents the culmination of a year of hard work, and marks the initiation of our Impracor Phase III study. With Agility as our clinical operations team, we have an experienced partner that will help us bring forward a new alternative therapy in the space of anti-inflammatory, pain-relieving drugs, to improve patient health and quality of life. We are delighted to be working with Dr. Neil Singla of Lotus Clinical Research, who has an excellent track record in conducting successful trials in the pain sector."

"We are excited that the Imprimis Phase III protocol was approved by an independent central ethics committee, Schulman Associates Institutional Review Board, Inc.," said Imprimis Chief Medical Officer Dr. Joachim Schupp. "This is an important milestone to commence our Phase III study in the third quarter of this year. The primary role of an IRB is to safeguard the rights, safety and welfare of participants in research. Agility Clinical and Lotus Clinical Research were instrumental in the final protocol and informed consent preparation."

"Helping innovative companies bring new treatments to patients is an important part of Agility's mission," said Ellen Morgan, CEO of Agility Clinical. "We are excited to be working with Imprimis and Lotus Clinical Research on this study. If approved, Impracor will provide patients suffering from osteoarthritis of the knee with an alternative to systemic NSAIDs for the management of their pain."

"We appreciate the opportunity to work with Imprimis Pharmaceuticals, Inc. and Agility Clinical on this important clinical trial," said Dr. Neil Singla, Owner of Lotus Clinical Research. "All parties have worked diligently over the past several months to design a robust protocol that will answer many critical regulatory and therapeutic questions concerning Impracor."

Imprimis has commenced the investigational site selection for training, qualification and study initiation.

About Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a specialty pharmaceutical company focused on the commercial development of compounded drug formulations. Through its exclusive strategic relationship with Professional Compounding Centers of America (PCCA), the largest compounding pharmacy organization in North America, Imprimis expects to use its proprietary Accudel drug delivery technologies, as well as proprietary drug formulations for new indications and market data obtained through PCCA, to identify and pursue pharmaceutical development opportunities where there is a significant unmet medical need utilizing the FDA 505(b)(2) regulatory pathway. Imprimis' most near term drug candidate, Impracor, is a Phase III product candidate that utilizes the Accudel topical cream formulation to deliver the active drug ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. For more information, visit http://imprimispharma.com/

About Agility Clinical, Inc.

Agility Clinical, Inc. was founded in 2012 with an experienced executive management team whose mission is to help small and virtual pre-clinical and clinical stage companies develop drugs and devices, particularly in the orphan drug category.  In addition to consulting, Agility provides customized full clinical trial services including project management, clinical operations, data management, biostatistics, medical, regulatory, and scientific affairs, medical writing and electronic source records (ESR).  The Agility team has a true appreciation for the challenges virtual companies face in obtaining the expertise they need.  Agility has established operations in Carlsbad, CA.  For more information, please visit www.agility-clinical.com.

About Lotus Clinical Research, LLC

Established in 2001, Lotus Clinical Research, LLC operates a 40 bed Phase I-3 privately owned research unit located on the 675–bed Huntington Hospital campus in Pasadena, California.  We have a significant therapeutic expertise in research studies involving acute pain, chronic pain and opioid induced constipation.  In addition to functioning as a research site, we provide analgesic protocol optimization services to industry sponsors which consist of: training tools for research subjects, educational materials for analgesic investigators/study staff, site identification/selection and protocol writing.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause Imprimis' results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no  obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact: Josh Berg
Imprimis Pharmaceuticals, Inc.
(858) 704-4041


'/>"/>
SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
2. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
3. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
4. Imprimis Names Two Experts To Its Science And Regulatory Board
5. Imprimis to Begin New Study of Its Topical Analgesic Drug
6. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
7. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
8. Imprimis Announces Key Leadership Appointments
9. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
10. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
11. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... injectable drug delivery systems, today announced that it will release ... December 31, 2015 after market close on February 9, 2016. ... call to discuss these financial results.    About ... --> About Unilife Corporation ...
(Date:2/8/2016)... NORTHBROOK, Ill. , Feb. 8, 2016  Astellas Pharma ... today announced the promotion of James Robinson as ... the company,s operations in North and South America ... president, Astellas Pharma US, representing the commercial organization in ... assumed in 2013. Masao Yoshida , who ...
(Date:2/8/2016)... Palatin Technologies, Inc. (NYSE MKT: PTN), ... for the treatment of diseases with significant unmet ... the United States Patent and Trademark Office (USPTO) ... Patent Application Serial Number 14/313,258 (the ,258 application).  ... female sexual dysfunction using the formulation and dose ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try ... Clay” the health benefits of integrating clay into a daily diet are numerous, as ... motivational speaker, Perry A~ has since dedicated her life to learning about the benefits ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com recently ... in Mole removal products. , Moles are derived from a cluster of melanin when ... all the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
(Date:2/8/2016)... ... , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal ... birthday on February 10th. During this time, people can achieve better health, greater ... people from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
Breaking Medicine News(10 mins):